SEC Company Response from Dianthus Therapeutics, (DNTH) — Jan 29, 2026
Dianthus Therapeutics, Inc. /DE/
Date: Jan. 29, 2026 · CIK: 0001690585 · Accession: 0001193125-26-029517
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293014
Letter
Re: Dianthus Therapeutics, Inc. Registration Statement on Form S-3 Filed January 28, 2026 File No. 333-293014 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Dianthus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company be accelerated to 4:00 p.m., Eastern Standard Time, on January 30, 2026 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Melanie Neary at (415) 393-8243.
January 29, 2026 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller
Very truly yours,
Dianthus Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 29, 2026 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller Re: Dianthus Therapeutics, Inc. Registration Statement on Form S-3 Filed January 28, 2026 File No. 333-293014 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Dianthus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company be accelerated to 4:00 p.m., Eastern Standard Time, on January 30, 2026 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Melanie Neary at (415) 393-8243. Very truly yours, Dianthus Therapeutics, Inc. By: /s/ Ryan Savitz Name: Ryan Savitz Title: Chief Financial Officer and Chief Business Officer cc: Marino Garcia, Dianthus Therapeutics, Inc. Adam Veness, Dianthus Therapeutics, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP